We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesFoghorn Therapeutics Inc

Foghorn Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.97 USD -0.12 ( 5.74%)
Last update at 2026-11-12T15:36:00Z
VOLUME
80967
Market Cap
312.05M

Momentum Score

…

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.96
Low
2.08
High
52 Week Price Range
2.70
Low
9.97
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Foghorn Therapeutics is a biotechnology company developing small-molecule therapeutics that target chromatin regulatory mechanisms to treat cancer and other diseases. Its proprietary discovery platform identifies modulators of chromatin biology and the company is advancing candidates across preclinical and clinical stages, which may support long-term growth through clinical progress and partnerships.
Key risks include clinical and regulatory failure, high cash burn and future financing needs, competition from larger biopharma, and uncertainty whether platform discoveries will translate into approved therapies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.09
Dividend Yield
-
Revenue TTM
33.90M
Revenue Per Share
0.81
Gross Profit TTM
-86.39M
Debt / Equity
-0.58
ROE
-470.38%
Net Debt
-35.26M
ROCE
-52.95%
Diluted EPS TTM
-2.20

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -108.88M -101.32M -68.80M -51.13M -26.34M
Net income -108.87M -103.23M -69.78M -51.67M -26.34M
Selling general administrative 30.75M 21.73M 11.25M 6.72M 4.82M
Gross profit 19.21M 1.32M 0.43M - -
Reconciled depreciation 3.32M 3.23M 1.33M 0.69M 0.38M
Ebit -120.46M -100.73M -68.53M -51.08M -25.94M
Ebitda -117.14M -94.95M -66.20M -49.90M -25.56M
Depreciation and amortization 3.32M 5.78M 2.33M 1.19M 0.38M
Non operating income net other 8.26M 1.32M 0.71M - -
Operating income -117.14M -100.73M -68.53M -51.08M -26.05M
Other operating expenses 136.37M 102.05M 68.96M 51.08M 26.05M
Interest expense 11.57M 1.91M 0.98M 0.54M 0.37M
Interest income 5.67M 2.55M 1.00M 0.49M 0.11M
Net interest income 5.67M 0.65M 0.02M -0.04M -0.26M
Income tax expense -0.01M 1.91M 0.98M 0.54M 0.08M
Total revenue 19.23M 1.32M 0.43M 0.00M 0.00M
Total operating expenses 136.37M 102.05M 68.96M 51.08M 26.05M
Cost of revenue 0.02M 0.00M - - -
Total other income expense net 8.26M -0.59M -0.27M -0.04M -0.03M
Net income from continuing ops -108.88M -101.32M -68.80M -51.13M -26.34M
Net income applicable to common shares -108.88M -101.32M -68.80M -51.13M -26.34M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 285.92M 404.88M 519.77M 255.59M 22.34M
Other current assets 6.12M 5.60M 5.27M 4.92M 1.36M
Total liab 363.11M 404.77M 422.90M 109.41M 110.36M
Total stockholder equity -77.19M 0.11M 96.87M 146.19M -88.02M
Other current liab 9.11M -11.38M 9.56M 9.16M 0.45M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -471.56M -373.14M -264.26M -162.94M -94.14M
Other liab - 304.03M 322.87M 12.55M -
Other assets 0.00M 4.09M 4.13M 2.58M 1.74M
Cash 80.34M 345.80M 101.14M 92.80M 14.98M
Total current liabilities 58.44M 336.82M 48.69M 18.85M 12.65M
Current deferred revenue 34.55M 336.82M 28.32M 2.02M 3.25M
Net debt -35.26M -294.29M -42.80M -10.80M 1.65M
Short term debt 8.52M 5.97M 6.99M 3.98M 5.51M
Short long term debt - - - - 4.15M
Short long term debt total 45.07M 51.51M 58.33M 82.00M 16.63M
Other stockholder equity 395.20M 377.23M 361.13M 53.53M 6.12M
Property plant equipment - 49.40M 56.08M 62.33M 3.71M
Total current assets 240.18M 345.80M 459.56M 190.69M 16.89M
Net tangible assets - 0.11M 96.87M 146.19M -88.02M
Short term investments 153.72M 293.58M 53.15M 92.97M -
Net receivables - 2.38M 300.00M 0.84M -
Long term debt - - - 19.65M 10.96M
Inventory - - -353.15M - -
Accounts payable 6.26M 5.41M 3.82M 3.68M 3.44M
Accumulated other comprehensive income -0.83M -3.99M -0.01M -0.01M -1.29M
Common stock total equity - 0.00M 0.00M 0.00M -
Retained earnings total equity - -373.14M -264.26M -162.94M -
Non currrent assets other 1.11M 9.69M 4.13M 2.58M 1.74M
Non current assets total 45.73M 59.09M 60.21M 64.91M 5.46M
Capital lease obligations 45.07M 51.51M 58.33M 62.34M 1.52M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -243.11M 39.49M -108.91M -0.96M -1.54M
Change to liabilities 3.06M 2.79M 15.04M 1.21M 1.28M
Total cashflows from investing activities -244.32M 36.17M -108.91M -0.96M -1.54M
Net borrowings - -21.20M 4.27M 7.98M 11.14M
Total cash from financing activities 1.76M 22.42M 217.47M 23.97M 51.77M
Change to operating activities -5.84M -303.17M 13.66M -0.01M 1.15M
Net income -108.88M -101.32M -68.80M -51.13M -26.34M
Change in cash -48.95M 8.34M 77.27M -23.33M 27.58M
Begin period cash flow 102.87M 94.53M 17.25M 40.59M 13.00M
End period cash flow 53.92M 102.87M 94.53M 17.25M 40.59M
Total cash from operating activities 193.61M -50.25M -31.29M -46.34M -22.65M
Issuance of capital stock 0.00M 42.20M 211.98M 15.29M 40.44M
Depreciation 3.32M 3.23M 1.33M 0.69M 0.38M
Other cashflows from investing activities - - 0.25M - -
Change to inventory - -3.17M - - -
Change to account receivables 300.00M -300.00M -300.00M -300.00M -
Sale purchase of stock 1.76M 43.62M 123.34M - -
Other cashflows from financing activities -244.32M 1.42M 110.88M -0.96M 52.59M
Change to netincome 14.34M 9.94M 7.48M 2.90M 0.89M
Capital expenditures 1.21M 3.31M 16.18M 0.97M 1.54M
Cash flows other operating 283.07M 34.94M 29.24M - -
Cash and cash equivalents changes -48.95M 8.34M 77.27M - -
Change in working capital 281.55M 33.44M 28.70M 1.20M 2.42M
Stock based compensation 14.34M 8.38M 2.96M 1.69M 0.73M
Other non cash items 3.29M 4.61M 4.44M 1.20M 0.12M
Free cash flow 192.40M -53.56M -47.47M -47.30M -24.19M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
FHTX
Foghorn Therapeutics Inc		 -0.12
5.74%		 1.97 - - 9.25 10.71 3.71 -1.21
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Foghorn Therapeutics Inc

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

500 Technology Square, Cambridge, MA, United States, 02139

617 586 3100

https://foghorntx.com

116

Name Title Year Born
Mr. Adrian H. B. Gottschalk Pres, CEO & Director 1976
Dr. Allan Reine M.D. Chief Financial Officer 1975
Dr. Samuel Agresta M.D., M.P.H. Chief Medical Officer 1973
Dr. Gerald R. Crabtree M.d. Founder & Member of Scientific Advisory Board NA
Dr. Steven F. Bellon Ph.D. Chief Scientific Officer 1965
Mr. Ben Strain VP of Investor Relations & Corp. Communications NA
Mr. Michael J. LaCascia Chief Legal Officer 1965
Mr. Saurabh Sewak Ph.D. VP of Corp. Devel. NA
Mr. Carlos Costa Chief People Officer NA
Ms. Fanny Cavalie Chief Strategy & Bus. Operations Officer 1978

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…